OTUB1-catalyzed deubiquitination of FOXM1 facilitates tumor progression and predicts a poor prognosis in ovarian cancer

Yiqin Wang; Xianrong Zhou; Midie Xu; Weiwei Weng; Qiongyan Zhang; Yusi Yang; Ping Wei; Xiang Du

doi:10.18632/oncotarget.9160

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

OTUB1-catalyzed deubiquitination of FOXM1 facilitates tumor progression and predicts a poor prognosis in ovarian cancer

Yiqin Wang, Xianrong Zhou, Midie Xu, Weiwei Weng, Qiongyan Zhang, Yusi Yang, Ping Wei _ and Xiang Du

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:36681-36697. https://doi.org/10.18632/oncotarget.9160

Metrics: PDF 4140 views | HTML 2299 views | ?

Abstract

Yiqin Wang1, Xianrong Zhou1, Midie Xu2,3,4,5, Weiwei Weng2,3,4,5, Qiongyan Zhang2,3,4,5, Yusi Yang2,3,4,5, Ping Wei2,4,6, Xiang Du2,3,4,5

1Department of Pathology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200044, China

2Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China

3Department of Pathology, Shanghai Medical College, Fudan University, Shanghai 200032, China

4Institute of Pathology, Fudan University, Shanghai 200032, China

5Institute of Biomedical Sciences, Fudan University, Shanghai 200032, China

6Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai 200032, China

Correspondence to:

Ping Wei, e-mail: [email protected]

Xiang Du, e-mail: [email protected]

Keywords: OTUB1, FOXM1, ovarian carcinoma, ubiquitination, deubiquitination

Received: August 12, 2015 Accepted: April 22, 2016 Published: May 4, 2016

ABSTRACT

Ubiquitination is essential for regulation of cell physiology, protein stability, and signal transduction [1]. Its dysregulation is an important factor in many diseases, including cancer. We explored the potential OTUB1-catalyzed deubiquitination of FOXM1, a transcription factor linked to carcinogenesis, and the biological consequence of that interaction in ovarian cancer. We found that FOXM1 is ubiquitinated by multiple polyUb chains and targeted for proteosomal degradation in a reaction dependent on its ubiquitination-required KEN box. Additionally, the OTUB1 N-terminus and catalytic triad bind to FOXM1, specifically catalyzing cleavage of the K48-specific ubiquitin linkage from FOXM1. Moreover, OTUB1-FOXM1 interaction drives tumor progression and OTUB1 expression predicts a poor prognosis in ovarian cancer. Our study suggests that inhibiting OTUB1-FOXM1 interaction is a potential new avenue for ovarian cancer therapy.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 9160

Publication Alerts

Research Papers:

OTUB1-catalyzed deubiquitination of FOXM1 facilitates tumor progression and predicts a poor prognosis in ovarian cancer

Abstract